News
KTTA
0.5220
+0.40%
0.0021
Weekly Report: what happened at KTTA last week (1109-1113)?
Weekly Report · 53m ago
Pasithea Therapeutics Price Target Raised to $4.00/Share From $3.00 by HC Wainwright & Co.
Dow Jones · 2d ago
Pasithea Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 2d ago
HC Wainwright & Co. Maintains Buy on Pasithea Therapeutics, Raises Price Target to $4
Benzinga · 2d ago
Pasithea's PAS-004 Shrinks Skin Tumors in All 15 Evaluable Patients
Benzinga · 2d ago
Pasithea Therapeutics price target raised to $4 from $3 at H.C. Wainwright
TipRanks · 2d ago
Pasithea Reports Tumor Shrinkage With PAS-004 In Neurofibromatosis Trial; Stock Up
NASDAQ · 2d ago
Pasithea Therapeutics presents clinical data from PAS-004-103 study
TipRanks · 2d ago
Pasithea’s PAS-004 Reduces Cutaneous Neurofibromas In All 15 Evaluable Participants, 41% Median Best Reduction, 46% At Planned Phase 2 Doses, With No Treatment-Related Serious Adverse Events
Benzinga · 3d ago
Weekly Report: what happened at KTTA last week (1102-1106)?
Weekly Report · 11/09 09:21
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 11/03 17:05
Short Interest Alert: Most and least shorted sub-$2B healthcare stock at the end of October
Seeking Alpha · 11/03 15:15
Pasithea gets FDA clearance for Phase 2 PAS-004 trial in skin neurofibromas
TipRanks · 11/03 14:13
Pasithea Therapeutics Says FDA Clears IND Application For Randomized, Placebo-Controlled Phase 2 Clinical Trial For PAS-004 In Patients With NF1 Associated Cutaneous Neurofibromas
Benzinga · 11/03 12:04
Weekly Report: what happened at KTTA last week (1026-1030)?
Weekly Report · 11/02 09:21
Pasithea Therapeutics Corp (KTTA) Receives a Buy from H.C. Wainwright
TipRanks · 10/26 10:38
Weekly Report: what happened at KTTA last week (1019-1023)?
Weekly Report · 10/26 09:21
Pasithea Therapeutics announces PAS-004 data at ESMO
TipRanks · 10/23 13:36
Pasithea Therapeutics Presents Phase I Dose-Escalation Trial Of PAS-004 Inhibitor; Announces No Dose Limiting Toxicities Seen; No Participant Discontinued PAS-004; No Grade 3, Higher Observed
Benzinga · 10/23 13:20
Weekly Report: what happened at KTTA last week (1012-1016)?
Weekly Report · 10/19 09:21
More
Webull provides a variety of real-time KTTA stock news. You can receive the latest news about Pasithea Therapeutics Corp through multiple platforms. This information may help you make smarter investment decisions.
About KTTA
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.